claudin 18.2 and fgfr2b as novel targets in gastric cancer
Published 1 year ago • 397 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
0:48
fgfr2b: a novel biomarker for patients with gastroesophageal cancer
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
0:57
combined inhibition of parp and vegf in gastric cancer
-
2:01
fgfr mutations
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
25:47
2017 ccf annual conference #10 - day 2 - fgfr pathway
-
1:52
iilustro: zolbetuximab, mfolfox6, and nivolumab combinations for gastrointestinal cancer
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
4:16
measuring tumor genes using cell-free dna - agbt 2015
-
2:27
triple angiokinase inhibition of vegf, pdgf and fgf receptors in cancer
-
1:10
tu2218, a tgfβ-ri and vegfr2 dual inhibitor, with pembrolizumab in solid tumors
-
3:03
targeted therapies for gastroesophageal adenocarcinoma
-
27:04
webinar: first-in human-studies of fgfr inhibitor kin-3248 and raf inhibitor kin-2787
-
10:39
ac22 - explore signaling pathways and combination therapy in fgfr2-activated cholangiocarcinoma
-
1:51
fgfr inhibitors